Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study


Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin ⩽ 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was… (More)
DOI: 10.1007/BF00216928


2 Figures and Tables

Slides referencing similar topics